Title:
BODY FLUID ANTIBODY BIOMARKER FOR HIGHLY SENSITIVE DETECTION OF RISK OF ONSET OF CEREBRAL INFARCTION
Document Type and Number:
WIPO Patent Application WO/2019/107256
Kind Code:
A1
Abstract:
The present invention provides an acquisition method for data relating to the onset of a cerebral infarction, said method being characterized by measuring the antibody levels for DIDO1 protein or a portion thereof, and/or CPSF2 protein or a portion thereof, in a body fluid sample which has been isolated from a living body. Also provided is a data acquisition kit for performing said method. The present invention enables signs linked to the onset of a cerebral infarction to be accurately discerned.
Inventors:
KURODA HIDEYUKI (JP)
NAKAMURA RIKA (JP)
TOMIYOSHI GO (JP)
HIWASA TAKAKI (JP)
YAMAGISHI KAZUMASA (JP)
TSUGANE SHOICHIRO (JP)
SAWADA NORIE (JP)
ISO HIROYASU (JP)
NAKAMURA RIKA (JP)
TOMIYOSHI GO (JP)
HIWASA TAKAKI (JP)
YAMAGISHI KAZUMASA (JP)
TSUGANE SHOICHIRO (JP)
SAWADA NORIE (JP)
ISO HIROYASU (JP)
Application Number:
PCT/JP2018/043090
Publication Date:
June 06, 2019
Filing Date:
November 22, 2018
Export Citation:
Assignee:
FUJIKURA KASEI KK (JP)
NAT CANCER CT (JP)
UNIV TSUKUBA (JP)
UNIV CHIBA NAT UNIV CORP (JP)
UNIV OSAKA (JP)
NAT CANCER CT (JP)
UNIV TSUKUBA (JP)
UNIV CHIBA NAT UNIV CORP (JP)
UNIV OSAKA (JP)
International Classes:
G01N33/53; C07K14/47
Foreign References:
| JP2011045334A | 2011-03-10 | |||
| JP2017143745A | 2017-08-24 | |||
| US20090047689A1 | 2009-02-19 | |||
| JP2012511895A | 2012-05-31 | |||
| JP2011211989A | 2011-10-27 | |||
| JP2017230639A | 2017-11-30 |
Other References:
CHA, J ET AL.: "Electro-hyperthermia inhibits glioma tumorigenicity through the induction of E2F1-mediated apoptosis", INT J HYPERTHERMIA ., vol. 31, no. 7, 14 September 2015 (2015-09-14), pages 784 - 792, XP055616002
KRAMER JHARCOS PPROHASZKA ZHORVATH LKARADI ISINGH MCSASZAR AROMICS LFUST G: "Frequencies of certain complement protein alleles and serum levels of anti-heat-shock protein antibodies in cerebrovascular diseases", STROKE, vol. 31, 2000, pages 2648 - 2652
MACHIDA TKUBOTA MKOBAYASHI EIWADATE YSAEKI N ET AL.: "Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX", J TRANSLAT MED, vol. 13, 2015, pages 71, XP021214300, DOI: 10.1186/s12967-015-0393-4
GOTO KSUGIYAMA TMATSUMURA RZHANG XMKIMURA R ET AL.: "Identification of cerebral infarction-specific antibody markers from autoantibodies detected in patients with systemic lupus erythematosus", J MOL BIOMARK DIAGNOS, vol. 6, 2015, pages 2
LIBBY PRIDKER PMHANSSON GK: "Progress and challenges in translating the biology of atherosclerosis", NATURE, vol. 473, 2011, pages 317 - 325, XP037159435, DOI: 10.1038/nature10146
KADOWAKI TYAMAUCHI TKUBOTA NHARA KUEKI KTOBE K: "Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome", J CLIN INVEST, vol. 116, 2006, pages 1784 - 1792, XP002560083, DOI: 10.1172/JCI29126
NAKANISHI NOKAMOTO MYOSHIDA HMATSUO YSUZUKI K ET AL.: "Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers", EUR J EPIDEMIOL, vol. 18, 2003, pages 523 - 530
HIWASA TMACHIDA TZHANG XMKIMURA RWANG H ET AL.: "Elevated levels of autoantibodies against ATP2B4 and BMP-1 in sera of patients with atherosclerosis-related diseases", IMMUNOME RES, vol. 11, 2015, pages 097
NAKAMURA RTOMIYOSHI GSHINMEN NKURODA HKUDO T ET AL.: "An anti-deoxyhypusine synthase antibody as a marker of atherosclerosis-related cerebral infarction, myocardial infarction, diabetes mellitus, and chronic kidney disease", SM ATHEROSCLER J, vol. 1, 2017, pages 1001
HIWASA TTOMIYOSHI GNAKAMURA RSHINMEN NKURODA H ET AL.: "Serum SH3BP5-specific antibody level is a biomarker of atherosclerosis", IMMUNOME RES, vol. 13, 2017, pages 2
LIANG KPKREMERS HMCROWSON CSSNYDER MRTHERNEAU TMROGER VLGABRIEL SE: "Autoantibodies and the risk of cardiovascular events", J RHEUMATOL, vol. 36, 2009, pages 2462 - 2469
MONTECUCCO FVUILLEUMIER NPAGANO SLENGLET SBERTOLOTTO MBRAUNERSREUTHER VPELLI GKOVARI EPANE BSPINELLA G: "Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability", EUR HEART J, vol. 32, 2011, pages 412 - 421
FESMIRE JWOLFSON-REICHLIN MREICHLIN M: "Effects of autoimmune antibodies anti-lipoprotein lipase, anti-low density lipoprotein, and anti-oxidized low density lipoprotein on lipid metabolism and atherosclerosis in systemic lupus erythematosus.", REV BRAS REUMATOL, vol. 50, 2010, pages 539 - 551
CARBONE FNENCIONI AMACH FVUILLEUMIER NMONTECUCCO F: "Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases", THROMB HAEMOST, vol. 109, 2013, pages 854 - 868
PALMER JPASPLIN CMCLEMONS PLYEN K, TATPATI 0RAGH, PKPAQUETTE TL: "Insulin antibodies in insulin-dependent diabetics before insulin treatment", SCIENCE, vol. 222, 1983, pages 1337 - 1339, XP055278620, DOI: 10.1126/science.6362005
ROLLINS KEVARADHAN KKDHATARIYA KLOBO DN: "Systematic review of the impact of HbAlc on outcomes following surgery in patients with diabetes mellitus", CLIN NUTR, 2015
BAEKKESKOV SAANSTOOT HCHRISTGAU SREETZ ASOLIMENA MSCASCALHO MFOLLI FRICHTER-OLSEN HDECAMILLI P: "Identification of the 64K autoantigen in insulin dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase", NATURE, vol. 347, 1990, pages 151 - 156, XP002141580, DOI: 10.1038/347151a0
PAYTON MAHAWKES CJCHRISTIE MR: "Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512", J CLIN INVEST, vol. 96, 1995, pages 1506 - 1511, XP002123340
See also references of EP 3719497A4
KRAMER JHARCOS PPROHASZKA ZHORVATH LKARADI ISINGH MCSASZAR AROMICS LFUST G: "Frequencies of certain complement protein alleles and serum levels of anti-heat-shock protein antibodies in cerebrovascular diseases", STROKE, vol. 31, 2000, pages 2648 - 2652
MACHIDA TKUBOTA MKOBAYASHI EIWADATE YSAEKI N ET AL.: "Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX", J TRANSLAT MED, vol. 13, 2015, pages 71, XP021214300, DOI: 10.1186/s12967-015-0393-4
GOTO KSUGIYAMA TMATSUMURA RZHANG XMKIMURA R ET AL.: "Identification of cerebral infarction-specific antibody markers from autoantibodies detected in patients with systemic lupus erythematosus", J MOL BIOMARK DIAGNOS, vol. 6, 2015, pages 2
LIBBY PRIDKER PMHANSSON GK: "Progress and challenges in translating the biology of atherosclerosis", NATURE, vol. 473, 2011, pages 317 - 325, XP037159435, DOI: 10.1038/nature10146
KADOWAKI TYAMAUCHI TKUBOTA NHARA KUEKI KTOBE K: "Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome", J CLIN INVEST, vol. 116, 2006, pages 1784 - 1792, XP002560083, DOI: 10.1172/JCI29126
NAKANISHI NOKAMOTO MYOSHIDA HMATSUO YSUZUKI K ET AL.: "Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers", EUR J EPIDEMIOL, vol. 18, 2003, pages 523 - 530
HIWASA TMACHIDA TZHANG XMKIMURA RWANG H ET AL.: "Elevated levels of autoantibodies against ATP2B4 and BMP-1 in sera of patients with atherosclerosis-related diseases", IMMUNOME RES, vol. 11, 2015, pages 097
NAKAMURA RTOMIYOSHI GSHINMEN NKURODA HKUDO T ET AL.: "An anti-deoxyhypusine synthase antibody as a marker of atherosclerosis-related cerebral infarction, myocardial infarction, diabetes mellitus, and chronic kidney disease", SM ATHEROSCLER J, vol. 1, 2017, pages 1001
HIWASA TTOMIYOSHI GNAKAMURA RSHINMEN NKURODA H ET AL.: "Serum SH3BP5-specific antibody level is a biomarker of atherosclerosis", IMMUNOME RES, vol. 13, 2017, pages 2
LIANG KPKREMERS HMCROWSON CSSNYDER MRTHERNEAU TMROGER VLGABRIEL SE: "Autoantibodies and the risk of cardiovascular events", J RHEUMATOL, vol. 36, 2009, pages 2462 - 2469
MONTECUCCO FVUILLEUMIER NPAGANO SLENGLET SBERTOLOTTO MBRAUNERSREUTHER VPELLI GKOVARI EPANE BSPINELLA G: "Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability", EUR HEART J, vol. 32, 2011, pages 412 - 421
FESMIRE JWOLFSON-REICHLIN MREICHLIN M: "Effects of autoimmune antibodies anti-lipoprotein lipase, anti-low density lipoprotein, and anti-oxidized low density lipoprotein on lipid metabolism and atherosclerosis in systemic lupus erythematosus.", REV BRAS REUMATOL, vol. 50, 2010, pages 539 - 551
CARBONE FNENCIONI AMACH FVUILLEUMIER NMONTECUCCO F: "Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases", THROMB HAEMOST, vol. 109, 2013, pages 854 - 868
PALMER JPASPLIN CMCLEMONS PLYEN K, TATPATI 0RAGH, PKPAQUETTE TL: "Insulin antibodies in insulin-dependent diabetics before insulin treatment", SCIENCE, vol. 222, 1983, pages 1337 - 1339, XP055278620, DOI: 10.1126/science.6362005
ROLLINS KEVARADHAN KKDHATARIYA KLOBO DN: "Systematic review of the impact of HbAlc on outcomes following surgery in patients with diabetes mellitus", CLIN NUTR, 2015
BAEKKESKOV SAANSTOOT HCHRISTGAU SREETZ ASOLIMENA MSCASCALHO MFOLLI FRICHTER-OLSEN HDECAMILLI P: "Identification of the 64K autoantigen in insulin dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase", NATURE, vol. 347, 1990, pages 151 - 156, XP002141580, DOI: 10.1038/347151a0
PAYTON MAHAWKES CJCHRISTIE MR: "Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512", J CLIN INVEST, vol. 96, 1995, pages 1506 - 1511, XP002123340
See also references of EP 3719497A4
Attorney, Agent or Firm:
SHIMURA Mitsuharu (JP)
Download PDF: